Globus Medical, Inc. has announced its preliminary sales results for the second quarter ending June 30, 2025. The company expects second quarter 2025 sales to reach approximately $745.3 million, marking an as-reported increase of 18.4% over the second quarter of 2024. When excluding the contribution from the recently acquired Nevro, Inc., base business sales are projected to be around $650.8 million, reflecting an as-reported increase of 3.3% over the same period in 2024. On a day-adjusted basis, base business sales rose by approximately 4.8% compared to the prior year quarter. Keith Pfeil, who was recently appointed as President and CEO, noted the significant improvement in the second quarter, particularly highlighting the 7.4% growth in the US Spine business on a day-adjusted basis over the previous year quarter. This growth contributed to the highest quarterly revenue result for the US Spine business since the merger with NuVasive in 2023. Globus Medical has reaffirmed its guidance for full-year 2025 revenue to be between $2.80 billion and $2.90 billion. The company also maintains its guidance for non-GAAP fully diluted earnings per share to fall within the range of $3.00 to $3.30. The detailed financial results for the second quarter are scheduled to be released after the market closes on August 7, 2025.